This HTML5 document contains 58 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n5http://linked.opendata.cz/resource/drugbank/drug/DB01602/identifier/pharmgkb/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01602/identifier/kegg-compound/
n20http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n16http://linked.opendata.cz/resource/drugbank/company/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01602/identifier/pubchem-compound/
n4http://linked.opendata.cz/resource/drugbank/drug/DB01602/identifier/pubchem-substance/
n18http://bio2rdf.org/drugbank:
n9http://linked.opendata.cz/resource/drugbank/drug/DB01602/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n22http://www.drugs.com/mtm/
n23http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n14http://linked.opendata.cz/resource/drugbank/drug/DB01602/identifier/chemspider/
owlhttp://www.w3.org/2002/07/owl#
n19http://linked.opendata.cz/ontology/mesh/
n6http://linked.opendata.cz/ontology/drugbank/
n7http://linked.opendata.cz/resource/drugbank/property/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01602/identifier/chebi/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/atc/
n10http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01602
rdf:type
n6:Drug
n6:description
Bacampicillin is a prodrug of ampicillin and is microbiologically inactive. It is absorbed following oral administration. During absorption from the gastrointestinal tract, bacampicillin is hydrolyzed by esterases present in the intestinal wall. It is microbiologically active as ampicillin, and exerts a bactericidal action through the inhibition of the biosynthesis of cell wall mucopeptides. It is used to cure infection of upper and lower respiratory tract; skin and soft tissue; urinary tract and acute uncomplicated gonococcal urethritis etc.
n6:group
approved
n6:indication
For infections at the following sites: upper and lower respiratory tract; skin and soft tissue; urinary tract and acute uncomplicated gonococcal urethritis, when due to sensitive strains of the following organisms: Gram-positive: streptococci (including <i>S. faecalis</i> and <i>S. pneumoniae</i>) and nonpenicillinase-producing staphylococci; Gram-negative: <i>H. influenzae</i>, <i>N. gonorrhoeae</i>, <i>E. coli</i>, <i>P. mirabilis</i>, <i>Salmonellae</i> and <i>Shigellae</i>.
owl:sameAs
n18:DB01602 n23:DB01602
dcterms:title
Bacampicillin
adms:identifier
n4:46507859 n5:PA164745461 n8:441397 n9:DB01602 n12:C08122 n13:2968 n14:390135
n6:mechanismOfAction
During absorption from the gastrointestinal tract, bacampicillin is hydrolyzed by esterases present in the intestinal wall. It is microbiologically active as ampicillin, and exerts a bactericidal action through the inhibition of the biosynthesis of cell wall mucopeptides.
n6:packager
n16:271B5ACA-363D-11E5-9242-09173F13E4C5 n16:271B5ACB-363D-11E5-9242-09173F13E4C5
n6:synonym
Bacampicilline Bacampicillinum Bacampicilina 1-[(Ethoxycarbonyl)oxy]ethyl (2S,5R,6R)-6-{[(2R)-2-amino-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate 1'-Ethoxycarbonyloxyethyl-(6-D-alpha-aminophenylacetamido)penicillanate
n6:salt
n6:synthesisReference
Luigi Ratti, "Novel synthesis route for bacampicillin." U.S. Patent US4619785, issued July, 1976.
n19:hasConcept
n20:M0058171
foaf:page
n22:bacampicillin.html
n6:IUPAC-Name
n7:271B5AD0-363D-11E5-9242-09173F13E4C5
n6:InChI
n7:271B5AD6-363D-11E5-9242-09173F13E4C5
n6:Molecular-Formula
n7:271B5AD5-363D-11E5-9242-09173F13E4C5
n6:Molecular-Weight
n7:271B5AD2-363D-11E5-9242-09173F13E4C5
n6:Monoisotopic-Weight
n7:271B5AD3-363D-11E5-9242-09173F13E4C5
n6:SMILES
n7:271B5AD4-363D-11E5-9242-09173F13E4C5
n6:Water-Solubility
n7:271B5ACE-363D-11E5-9242-09173F13E4C5
n6:logP
n7:271B5ACF-363D-11E5-9242-09173F13E4C5 n7:271B5ACC-363D-11E5-9242-09173F13E4C5
n6:logS
n7:271B5ACD-363D-11E5-9242-09173F13E4C5
n10:hasATCCode
n11:J01CA06
n6:H-Bond-Acceptor-Count
n7:271B5ADC-363D-11E5-9242-09173F13E4C5
n6:H-Bond-Donor-Count
n7:271B5ADD-363D-11E5-9242-09173F13E4C5
n6:InChIKey
n7:271B5AD7-363D-11E5-9242-09173F13E4C5
n6:Polar-Surface-Area--PSA-
n7:271B5AD8-363D-11E5-9242-09173F13E4C5
n6:Polarizability
n7:271B5ADA-363D-11E5-9242-09173F13E4C5
n6:Refractivity
n7:271B5AD9-363D-11E5-9242-09173F13E4C5
n6:Rotatable-Bond-Count
n7:271B5ADB-363D-11E5-9242-09173F13E4C5
n6:absorption
Absorbed following oral administration.
n6:affectedOrganism
Enteric bacteria and other eubacteria
n6:casRegistryNumber
50972-17-3
n6:category
n6:Bioavailability
n7:271B5AE2-363D-11E5-9242-09173F13E4C5
n6:Ghose-Filter
n7:271B5AE4-363D-11E5-9242-09173F13E4C5
n6:MDDR-Like-Rule
n7:271B5AE5-363D-11E5-9242-09173F13E4C5
n6:Melting-Point
n7:271B5AE6-363D-11E5-9242-09173F13E4C5
n6:Number-of-Rings
n7:271B5AE1-363D-11E5-9242-09173F13E4C5
n6:Physiological-Charge
n7:271B5AE0-363D-11E5-9242-09173F13E4C5
n6:Rule-of-Five
n7:271B5AE3-363D-11E5-9242-09173F13E4C5
n6:Traditional-IUPAC-Name
n7:271B5AD1-363D-11E5-9242-09173F13E4C5
n6:pKa--strongest-acidic-
n7:271B5ADE-363D-11E5-9242-09173F13E4C5
n6:pKa--strongest-basic-
n7:271B5ADF-363D-11E5-9242-09173F13E4C5